All stock lists
Airsculpt Technologies, Inc. (NASDAQ:AIRS)
US · Delayed Price · Currency is USD
Healthcare · Medical - Care Facilities
$0.72-$0.09 (-10.60%)
Market cap
$53.2M
Insider Score
Health Score
Analyst consensus
Listed since
Oct 29, 2021
Website
Insider Score
62/ 100
AIRS Insider Score
Bullish1 qualifying trade · 1 insider · $24.05K bought in the last 90 days
Financial Health Score
Weak
From AIRS’s reported statements · Q3 2026 (trailing 12 months)
Profitability7 / 20
Loses money on what it sells.
- Revenue
- $147.7M
- Net income
- -$9.4M
- Net margin
- -6.4%
Leverage0 / 20
Heavily indebted for what it earns.
- Total debt
- $65.0M
- Cash
- $15.2M
- Net debt / EBITDA
- 9.19x
Liquidity5 / 20
Owes more within a year than it holds to pay it.
- Current assets
- $23.1M
- Current liabilities
- $27.2M
- Current ratio
- 0.85
Cash generation10 / 20
Roughly cash-neutral.
- Operating cash flow
- -$2.0M
- Free cash flow
- -$2.5M
- FCF margin
- -1.7%
Dilution & runway7 / 20
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 72.5M
- Share growth (1y)
- 16.2%
- Cash runway
- 92 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
AIRS Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | $31.94 M | $42.90 M | $39.39 M | $33.44 M | $34.99 M | $44.01 M |
| Revenue Growth (YoY) | -8.71 % | -2.53 % | 0.05 % | -14.64 % | -17.76 % | -13.71 % |
| Cost of Revenue | $12.91 M | $19.51 M | $18.61 M | $13.68 M | $12.06 M | $15.50 M |
| Gross Profit | $19.03 M | $23.39 M | $20.78 M | $19.77 M | $22.93 M | $28.51 M |
| SG&A Expense | $20.26 M | $23.42 M | $22.58 M | $18.22 M | $22.32 M | $24.37 M |
| R&D Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expenses | $23.17 M | $23.10 M | $21.63 M | $21.29 M | $32.68 M | $27.73 M |
| Operating Income | -$4.14 M | $294.00 K | -$849.00 K | -$1.52 M | -$9.75 M | $786.00 K |
| Pretax Income | -$5.38 M | -$1.21 M | -$2.86 M | -$2.49 M | -$7.87 M | -$776.00 K |
| Tax Provision | $1.79 M | -$101.00 K | -$465.00 K | -$3.77 M | $1.64 M | -$185.00 K |
| Net Income | -$7.17 M | -$1.11 M | -$2.40 M | $1.28 M | -$9.51 M | -$591.00 K |
| EPS (Basic) | -$0.10 | -$0.02 | -$0.03 | $0.02 | -$0.15 | -$0.01 |
| EPS (Diluted) | -$0.10 | -$0.02 | -$0.03 | $0.02 | -$0.15 | -$0.01 |
| Shares Outstanding | 72.54 M | 70.79 M | 69.46 M | 60.45 M | 62.44 M | 59.59 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.